Manuel Perez Alonso

Manuel Perez Alonso is a full Professor in the Department of Genetics at the Faculty of Biological Sciences, University of Valencia. He is a principal investigator in the Human Translational Genomics research group (GT) and affiliated with the University Institute of Biotechnology and Biomedicine (BIOTECMED). His work integrates molecular genetics, RNA biology, and therapeutic development for neuromuscular disorders.

Research Interests: Dr. Perez Alonso's research focuses on the molecular mechanisms of myotonic dystrophy, particularly the role of toxic CUG/CCUG RNA repeats and their impact on splicing regulation via MBNL proteins. He employs Drosophila, mouse, and human cell models to study disease pathogenesis and to develop novel therapeutic strategies, including antagomiRs, peptide-based inhibitors, and small molecules. His work bridges basic science and clinical applications in genomic medicine.

The recent publications highlight a consistent trend toward translational therapeutics, with a strong emphasis on RNA-targeted interventions, in vivo validation in multiple models, and functional rescue of splicing defects. Key themes include microRNA modulation, peptide delivery, and in silico drug discovery, reflecting a multidisciplinary approach to treating myotonic dystrophy.

Scientific Contributions:

• Extensive publication record in RNA biology and genetic disease models.
• Pioneering use of Drosophila for high-throughput drug screening in myotonic dystrophy.
• Contributions to preimplantation genetic diagnosis (PGD) and molecular diagnostics.
• Leadership in the Human Translational Genomics group at BIOTECMED.

Advising and Grants: While specific students and grant details are not listed in the provided text, his long-standing research group and continuous publication output suggest active mentorship of graduate students and postdoctoral researchers, as well as sustained funding for his work in genetic disease mechanisms and therapy development.

Laboratories and Teams: Dr. Perez Alonso leads the GT Human Translational Genomics group at the University of Valencia, operating within the BIOTECMED institute. His team utilizes a combination of molecular genetics, cell biology, and bioinformatics to investigate RNA toxicity and develop therapeutic strategies for myotonic dystrophy.